Rocky Hill, CT, United States of America

Andrew P Degnan

This inventor holds 20 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 12 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew P Degnan. Retrieved from https://idiyas.com/inventor/andrew-p-degnan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 8)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 66(Granted Patents)

Location History:

New Haven, CT (US) (2007 - 2010)
Rocky Hill, CT (US) (2008 - 2017)
Jamison, PA (US) (2019 - 2023)

Company Filing History:

18 out of 3,737

Bristol-Myers Squibb Compnay

patents

2 out of 41

Bristol Meyers Squibb Company

patents

Years Active: 2007-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570671 - SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER (2026-03-10),

2. 12486267 - Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis (2025-12-02),

3. RE49735 - Oxazolidinones as modulators of MGLUR5 (2023-11-28),

4. 11548870 - Compounds useful as inhibitors of helios protein (2023-01-10),

5. 11166959 - Isofuranone compounds useful as HPK1 inhibitors (2021-11-09),

6. 10174024 - 5H-pyrido[3,2-B]indole compounds as anticancer agents (2019-01-08),

7. 9751879 - Tricyclic compounds as anticancer agents (2017-09-05),

8. 9725449 - Tricyclic compounds as anticancer agents (2017-08-08),

9. 9695176 - Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists (2017-07-04),

10. 9688669 - Oxazolidinones as modulators of mGluR5 (2017-06-27),

11. 8691821 - Oxazolidinones as modulators of mGluR5 (2014-04-08),

12. 8383821 - NK-1 and serotonin transporter inhibitors (2013-02-26),

13. 8026257 - Substituted heterocyclic ethers and their use in CNS disorders (2011-09-27),

14. 7842808 - Anti-migraine spirocycles (2010-11-30),

15. 7772244 - Therapeutic agents for the treatment of migraine (2010-08-10),

Title: The Innovative Contributions of Andrew P Degnan

Introduction

Andrew P Degnan is a notable inventor based in Rocky Hill, CT (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 18 patents to his name, Degnan has made strides in developing compounds that target various disorders of the central nervous system and other medical conditions.

Latest Patents

Among his latest patents, Degnan has developed oxazolidinones as modulators of mGluR5. This patent relates to compounds that serve as ligands, agonists, and partial agonists for the mGluR5 receptor, which may be beneficial in treating various central nervous system disorders. Another significant patent involves compounds useful as inhibitors of Helios protein. These compounds are designed to inhibit Helios protein and are applicable in treating viral infections and proliferative disorders, such as cancer.

Career Highlights

Degnan has had a distinguished career, working with prominent companies such as Bristol-Myers Squibb Company. His work has focused on innovative pharmaceutical solutions that address critical health issues.

Collaborations

Throughout his career, Degnan has collaborated with esteemed colleagues, including John E Macor and George O Tora. These partnerships have contributed to the advancement of his research and the development of his patented compounds.

Conclusion

Andrew P Degnan's innovative work in pharmaceuticals has led to the development of important compounds that hold promise for treating various medical conditions. His contributions continue to impact the field significantly.

Profile summary based on public USPTO records.